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Abstract
Background: In ischemic stroke, blood-brain barrier (BBB) regulations, typically involving matrix metalloproteinases
(MMPs) and inhibitors (TIMPs) as mediators, became interesting since tissue plasminogen activator (tPA)-related BBB
breakdown with risk of secondary hemorrhage was considered to involve these mediators too. Despite high clinical
relevance, detailed interactions are purely understood. After a pilot study addressing hyperoxia as potential
neuroprotective co-treatment to tPA, we analyzed interrelations between BBB permeability (BBB-P), MMPs and TIMPs.
Findings: Rats underwent embolic middle cerebral artery occlusion (eMCAO) and treatment with normobaric
(NBO) or hyperbaric oxygen (HBO), tPA, tPA+HBO, or no treatment. BBB-P was assessed by intravenously applied
FITC-albumin at 4 or 24 hours. MMP-2/-9 and TIMP-1/-2 serum levels were determined at 5 or 25 hours. Time
point-corrected partial correlations were used to explore interrelations of BBB-P in ischemic regions (extra-/
intravasal FITC-albumin ratio) and related serum markers. BBB-P correlated positively with MMP-2 and MMP-9 in
controls, whereas hyperoxia led to an inverse association, most pronounced for HBO/MMP-9 (r = -0.606; P < 0.05).
As expected, positive coefficients were observed after treatment with tPA. Co-treatment with HBO attenuated and
in part reversed this effect, but to a lower degree than HBO alone. Amongst MMPs and TIMPs, significant
associations shifted from MMP-9 to -2 when comparing treatment with HBO/tPA and tPA+HBO. TIMPs were
significantly interrelated after tPA, tPA+HBO, and interestingly, HBO alone.
Conclusions: HBO was found to reverse the positively directed interrelation of BBB-P and MMPs after eMCAO, but
this effect failed to sustain in the expected amount when HBO and tPA were given simultaneously.
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Findings
Multiple clinical trials have proven the efficacy of tissue
plasminogen activator (tPA) in the treatment of acute
focal cerebral ischemia [1]. Apart from its beneficial
recanalizing actions, tPA has also detrimental effects
contributing to blood-brain barrier (BBB) disruption in
ischemia-affected brain tissue [2-4] with an increased
risk of secondary hemorrhage and poor outcome [5,6].
Enzymes, e.g., matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs), are considered as key factors
regulating the BBB integrity [7,8]. Thereby, MMPs pos-
sess both destructive abilities in earlier phases of ische-
mia and regenerative properties (e.g., remodeling) in
later phases [9], which implicate complex interactions in
t h et i m ec o u r s eo fi s c h e m i cs t r o k e .I n t e r e s t i n g l y ,t P A
was found to directly increase MMP levels in experi-
mental and clinical stroke [4,10-12], which is considered
as a main tPA-related mechanism of BBB breakdown
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protective strategies with the aim to selectively attenuate
tPA side effects [14]. In this regard, treatment with
hyperoxia - the application of 100% oxygen under nor-
mal (normobaric oxygen; NBO) or elevated ambient
pressure (hyperbaric oxygen; HBO) [15] - was discussed
as potential co-treatment [16]. This rationale based on
the reported positive effects of hyperoxia in experimen-
tal stroke, e.g., reduced degradation of BBB components,
inhibition of MMP-9 upregulation [17], and decreased
secondary hemorrhage when tPA was given following
hyperoxia [18,19]. Our group has recently demonstrated
that hyperoxia, tPA and especially their simultaneous
application differentially affects BBB permeability and
alters plasma concentrations of MMPs and TIMPs [20].
Considering the potential clinical use of hyperoxia in
acute ischemic stroke - especially in combination with
tPA - we aimed to further clarify mechanisms of ische-
mia-related BBB alterations including the role of
involved MMPs and TIMPs. Here, we tested the hypoth-
esis that tPA and hyperoxia (i.e. NBO or HBO) influ-
ence the interrelations between BBB permeability,
MMP-2/-9 and TIMP-1/-2 in the early phase of experi-
mental focal cerebral ischemia.
For this purpose, we retrospectively analyzed data
from our previous work [20]. The underlying study and
the associated experimental animals procedures were
approved by local authorities and conducted according
to the 86/609/EEC. In detail, male Wistar rats under-
went focal cerebral ischemia by right-sided embolic mid-
dle cerebral artery occlusion (eMCAO) as described
previously [20,21]. Two hours after eMCAO, the ani-
mals were treated with 60 minutes of NBO or HBO (2.4
absolute atmospheres) in a special oxygen chamber
(Sayers/Hebold, Cuxhaven, Germany), tPA (Actilyse,
Boehringer, Ingelheim, Germany; 9 mg/kg body weight
intravenously over 30 minutes), combined tPA and
HBO (tPA+HBO), or received no treatment (control).
F o u ro r2 4h o u r sa f t e ri s c h e m i ao n s e tvia eMCAO, 20
mg of FITC-albumin (Sigma, Taufkirchen, Germany; in
1 mL physiological saline solution [NaCl]) was adminis-
tered intravenously. After an additional circulation per-
iod of usually 1 hour, the animals were deeply
anesthetized and blood samples for MMP-2, -9, TIMP-1
and -2 serum concentrations were obtained transcar-
dially, followed by perfusion with NaCl and 4% parafor-
maldehyde in phosphate-buffered saline. Tissue
preparation and quantification of BBB integrity in ische-
mia-affected brain regions using FITC-albumin as per-
meability marker were described previously [20,22]. The
resulting extra-/intravasal ratio was utilized for calcula-
tions in the present study. Overall, data from 78 animals
were used for statistical analyses of interrelations
between the extra-/intravasal FITC-albumin ratio as
surrogate for ischemia-related BBB permeability, and
serum concentrations of MMPs and TIMPs via time
point-corrected (survival period) partial correlations.
Calculations were made with SPSS 18.0 (SPSS Inc., an
I B MC o m p a n y ,C h i c a g o ,I L ) ;aP < 0.05 was considered
statistically significant.
We first focused on interrelations between the ische-
mia-induced changes in BBB permeability, MMP-2 and
-9 in controls (Figure 1) to explore the natural patho-
physiology in the applied model of experimental stroke.
Non-significant but positive partial correlation coeffi-
cients were observed for both MMPs investigated, parti-
cularly MMP-2 (r = 0.317), indicating an unidirectional
association between BBB permeability and plasma MMP
concentrations. Figure 1 further displays the results after
treatment with hyperoxia (NBO or HBO), tPA and its
combination with HBO. While we observed in NBO-
treated animals negative correlation coefficients for both
MMP-2 and -9, HBO resulted in a significant negative
correlation (r = 0.606; P = 0.022) for MMP-9,
Figure 1 Time point-corrected partial correlation coefficients
between the extra-/intravasal FITC-albumin ratio as surrogate
for blood-brain barrier permeability in ischemia-affected brain
regions and matrix metalloproteinase (MMP)-2 (A) as well as
MMP-9 (B) serum levels depending on treatment. Underlying
degrees of freedom (df): In both (A) and (B) for controls n = 13, for
NBO n = 13, for HBO n = 12, for tPA n = 11, and for tPA+HBO n =
13. Coefficient significance level: *: P < 0.05.
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ability and MMP levels. As expected, treatment with
tPA led to unidirectional associations of BBB permeabil-
ity and MMP levels as indicated by positive correlation
coefficients, again pronouncing MMP-9. Interestingly,
treatment with tPA+HBO resulted in inverse associa-
tions between BBB permeability and both MMPs when
compared to tPA alone, but this effect was much lower
as in groups treated with NBO or HBO alone. Second,
we focused on interrelations between MMPs and TIMPs
in all animal groups exploring the natural relationship
of these enzymes in untreated focal cerebral ischemia
(Table 1), and after different treatments (Table 2 and 3).
In controls, non-significant correlation coefficients were
found, although values ranged from -0.314 (MMP-9 and
TIMP-2) to 0.345 (MMP-2 and TIMP-2). A comparable
situation was noted in NBO-treated animals (Table 2,
upper right), but interestingly, HBO led to interrelations
with significant coefficients (Table 2, lower left).
Thereby, almost identical positive correlation coeffi-
cients of about 0.7 were obtained between TIMP-1 and
MMP-9, TIMP-2 and MMP-9 as well as TIMP-1 and
-2, clearly indicating treatment-specific alterations when
compared to controls (Table 1). For tPA (Table 3, upper
right), significant coefficients of about 0.7 were detected
between TIMP-2 and MMP-9 as well as TIMP-1 and -2.
In contrast, administration of tPA+HBO (Table 2, lower
left) did not affect the MMP-9 route significantly, but
provided significant and positively directed correlation
coefficients (about 0.6 and 0.8) between MMP-2 and
TIMP-1 as well as TIMP-2. Notably, TIMP-1 and -2
were also significantly positively correlated after com-
bined treatment with tPA and HBO, which has already
been noted for tPA and HBO alone with nearly the
same coefficients (about 0.76).
Despite its retrospective design, the present study pro-
vided clinically relevant insights in interactions of
stroke-related BBB permeability with associated MMPs
and TIMPs in consideration of tPA as approved treat-
ment for ischemic stroke [1], and hyperoxia as potential
neuroprotective co-treatment [16]. Thereby, HBO was
chosen since a previous report has already tested the
combination of NBO and tPA [23]. Concerning transla-
tional aspects, efforts were made to use an embolic
model for focal cerebral ischemia, representing probably
the best comparability to the human pathophysiology
[24]. Furthermore, BBB-related changes based on the
leakage marker FITC-albumin and BBB-associated
serum markers were assessed simultaneously, which
required specific brain tissue preparations for immuno-
fluorecence labeling [22] and significant correlations
between plasma and brain levels of MMPs, as shown by
a previous study for MMP-9 [25].
The first main finding of the present study was the
ability of hyperoxia to reverse the (in controls positively
directed) association of BBB permeability, MMP-2 and
-9 when administered 2 hours after ischemia onset. This
e f f e c tw a sm o s tp r o n o u n c e df o rM M P - 9a n dt r e a t m e n t
with HBO, suggesting a specific influence of HBO on
BBB regulation. Based on the presented data the pre-
viously reported tendency for BBB stabilization following
HBO administration 2 hours after eMCAO [20] might
be attributed to an interruption of the MMP-9-related
increase of BBB permeability. This view is supported by
former studies showing an attenuated MMP-9 upregula-
tion after experimental stroke treated with hyperoxia
Table 1 Time point-corrected partial correlation
coefficients between BBB-related serum markers in
control animals.
MMP-2 MMP-9 TIMP-1 TIMP-2
MMP-2 - 0.199
P = 0.478
0.083
P = 0.768
0.345
P = 0.207
MMP-9 - -0.055
P = 0.844
-0.314
P = 0.254
TIMP-1 - 0.302
P = 0.274
TIMP-2 -
Underlying degrees of freedom (df): n = 13.
Table 2 Time point-corrected partial correlation
coefficients between BBB-related serum markers in
animals treated with NBO (upper right) or HBO (lower
left).
MMP-2 MMP-9 TIMP-1 TIMP-2
MMP-2 - 0.240
P = 0.389
0.217
P = 0.437
0.071
P = 0.801
MMP-9 0.130
P = 0.657
- -0.161
P = 0.567
0.341
P = 0.214
TIMP-1 0.012
P = 0.967
0.710
P = 0.004
- 0.024
P = 0.932
TIMP-2 0.085
P = 0.773
0.626
P = 0.017
0.764
P = 0.001
-
Underlying degrees of freedom (df): for NBO n = 13, for HBO n = 12.
Table 3 Time point-corrected partial correlation
coefficients between BBB-related serum markers in
animals treated with tPA alone (upper right) or tPA+HBO
(lower left).
MMP-2 MMP-9 TIMP-1 TIMP-2
MMP-2 - 0.277
P = 0.360
0.325
P = 0.279
0.445
P = 0.128
MMP-9 -0.045
P = 0.873
- 0.425
P = 0.148
0.725
P = 0.005
TIMP-1 0.628
P = 0.012
0.155
P = 0.580
- 0.757
P = 0.003
TIMP-2 0.834
P = 0.000
0.306
P = 0.268
0.760
P = 0.001
-
Underlying degrees of freedom (df): for tPA n = 11, for tPA+HBO n = 13.
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ment with tPA leads to an increase in BBB permeability
that is mainly caused by MMP-9 activation [2,10,12],
which was confirmed by our data (positive correlation
coefficient between BBB permeability and MMP-9).
Concerning the potential neuroprotective effect of HBO
when simultaneously applied to tPA and its clinical
potential, we found that this approach attenuated, and
actually reversed the effect of tPA in part, but this effect
w a sl e s sp r o n o u n c e dt h a na fter treatment with HBO
alone. However, these data suggest that HBO simulta-
neously applied to tPA starting 2 hours after experimen-
tal stroke does not result in the assumed
neuroprotective effect via a significant prevention of the
MMP-9-related increase in BBB permeability. Moreover,
this finding should be seen in context with our previous
study [20] which noted a tendency towards increased
BBB permeability and plasma concentrations of MMPs
and TIMPs when addressed separately and, therefore,
opens up a critical perspective on this combined
approach.
The second part of the present study addressed inter-
relations of MMPs and TIMPs. Here, we found mainly
week and non-significant associations in controls and
NBO-treated animals. This situation clearly changed
after treatment with HBO, tPA and the combined
approach: HBO and tPA led to significant positive asso-
ciations between MMP-9 and TIMP-2, and in part
MMP-9 and TIMP-1. However, treatment with tPA
+HBO resulted in a shift towards significant positive
associations between MMP-2 and TIMP-1/-2, while
MMP-9 provided non-significant coefficients. Interest-
ingly, a significant correlation coefficient between
TIMP-1 and -2 was found for all types of treatment
with the exception of NBO. Why this association was
also present for HBO without concomitant tPA treat-
ment remains open and requires further evaluation.
Unfortunately, a clear interpretation of these mediator-
related changes is still impeded by the complexity of
MMP activation, including the expression of pro-MMPs,
the interference with other MMPs (e.g., MMP-3) [4],
and non-selective inhibitory processes by TIMPs [8]
with reported positive and negative effects depending on
the time course of ischemia [3].
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